Compile Data Set for Download or QSAR
Report error Found 151 Enz. Inhib. hit(s) with all data for entry = 1230
TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM312994(US10166216, Compound 4 | N3-(3-chloro-4-(2-(pyrrol...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM312999(US10166216, Compound 9 | N3-(4-(2-(pyrrolidin-1-yl...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313009(N-{2-[(4aR,6S,8aR)-2-amino-6-methyl-4,4a,5,6-tetra...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313011(US10166216, Compound 21 | N-{2-[(4aR,6S,8aR)-2-ami...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313015(US10166216, Compound 25 | N-{2-[(4aR,6S,8aR)-2-ami...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313016(N-{2-[(4aR,6S,8aR)-2-amino-6-methyl-4,4a,5,6-tetra...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313027(N-{2-[(4aR,6S,8aR)-2-amino-6-methyl-4,4a,5,6-tetra...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313029(N-{2-[(4aR,6S,8aR)-2-amino-6-methyl-4,4a,5,6-tetra...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313030(US10166216, Compound 40 | N-{2-[(4aR,6S,8aR)-2-ami...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313062(US10166216, Compound 41 | N3-(4-(2-(pyrrolidin-1-y...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313065(US10166216, Compound 44 | 1-(2-chloro-6,7-dimethox...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313066(US10166216, Compound 45 | 1-(6,7-dimethoxyquinazol...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313067(US10166216, Compound 46 | N3-(4-(2-(2,5-dimethylpy...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313069(US10166216, Compound 48 | 1-(6-chloroquinazolin-4-...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313070(US10166216, Compound 49 | 1-(2-chloro-6,7-dihydro-...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313071(US10166216, Compound 50 | 1-(isoquinolin-1-yl)-N3-...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313072(US10166216, Compound 51 | N3-(4-(2-(pyrrolidin-1-y...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313073(US10166216, Compound 52 | 1-(6-phenylthieno[3,2-d]...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313074(US10166216, Compound 53 | N3-(4-(2-(pyrrolidin-1-y...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313075(US10166216, Compound 54 | N3-(4-(2-(pyrrolidin-1-y...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313076(US10166216, Compound 55 | N3-(3-fluoro-4-(2-(pyrro...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313077(US10166216, Compound 56 | 1-(benzo[d]thiazol-2-yl)...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313078(US10166216, Compound 57 | N3-(3-fluoro-4-(2-(pyrro...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313079(US10166216, Compound 58 | N3-(3-fluroo-4-(2-(pyrro...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313080(US10166216, Compound 59 | N3-(3-chloro-4-(2-(pyrro...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313081(US10166216, Compound 60 | 1-(2-chloro-7-methylthie...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313082(US10166216, Compound 61 | 1-(5,6,7,8-tetrahydroben...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313083(US10166216, Compound 62 | N3-(3-chloro-4-(2-(pyrro...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313084(US10166216, Compound 63 | 1-(6-fluoroquinazolin-4-...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313085(US10166216, Compound 64 | N3-(4-(2-(pyrrolidin-1-y...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313086(US10166216, Compound 65 | 1-(2-methylquinazolin-4-...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313087(US10166216, Compound 66 | 1-(6,7-dihydro-5H-cyclop...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313088(US10166216, Compound 67 | N3-(3-chloro-4-(2-(pyrro...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313089(US10166216, Compound 68 | N3-(3-fluoro-4-(2-(pyrro...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313090(US10166216, Compound 69 | 1-(furo[3,2-c]pyridin-4-...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313092(US10166216, Compound 71 | 1-(benzothieno[3,2-d]pyr...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313096(US10166216, Compound 75 | 1-(5,6-dihydrobenzo[h]ci...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313098(US10166216, Compound 77 | 1-(6,7-dimethoxyisoquino...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313099(US10166216, Compound 78 | 5-(5-amino-3-(4-(2-(pyrr...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313103(US10166216, Compound 175 | 1-(2,6-dichlorothieno[3...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313104(US10166216, Compound 176 | 1-(2-chlorothieno[2,3-d...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313105(US10166216, Compound 177 | 1-(2-chlorothieno[3,2-d...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313108(US10166216, Compound 83 | N5-(4-(4-cyclohexylpiper...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313109(US10166216, Compound 86 | 1-(6-chloroquinazolin-4-...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313111(US10166216, Compound 100 | N5-(4-(4-(bicyclo[2.2.1...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313113(US10166216, Compound 205 | 1-(phenanthridin-6-yl)-...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313124(US10166216, Compound 153 | 1-(6,7-dimethoxyquinazo...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313125(US10166216, Compound 155 | 1-(isoquinolin-1-yl)-N3...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313127(US10166216, Compound 158 | 1-(6,7-dimethoxyquinazo...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM313128(US10166216, Compound 159 | N3-(3-chloro-4-morpholi...)
Affinity DataIC50: 1.00E+3nMAssay Description:The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemilumines...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 151 total ) | Next | Last >>
Jump to: